alexa Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir ritonavir: systematic review and meta-analysis of randomized controlled trials.
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): Carey D, Amin J, Boyd M, Petoumenos K, Emery S, Carey D, Amin J, Boyd M, Petoumenos K, Emery S

Abstract Share this page

Abstract OBJECTIVES: To compare lipid profiles in HIV-infected adults receiving atazanavir-based regimens. METHODS: We conducted a systematic review of randomized controlled trials (RCTs) comparing atazanavir or atazanavir/ritonavir with a comparator and evaluated lipids at 48 weeks. We searched MEDLINE, EMBASE, CENTRAL, LILACS, Current Controlled Trials, National Institutes of Health Clinical Trials Registry, trials at AIDSinfo and HIV conference proceedings to May 2009. Standardized mean difference (SMD) between study arms in change from baseline to week 48 in lipid parameters was determined weighted by study size and 95\% confidence intervals (CI) were calculated. RESULTS: Nine eligible RCTs were identified (n = 3346). SMDs (mmol/L) in four RCTs comparing atazanavir/ritonavir with a ritonavir-boosted protease inhibitor were: total cholesterol, -0.62 (95\% CI -0.72, -0.51); low-density lipoprotein (LDL) cholesterol, -0.31 (95\% CI -0.44, -0.17); high-density lipoprotein (HDL) cholesterol, -0.16 (95\% CI -0.27, -0.06); non-HDL cholesterol, -0.58 (95\% CI -0.69, -0.48); and triglycerides, -0.46 (95\% CI -0.58, -0.34). Atazanavir compared with non-atazanavir (three RCTs) found lower total, LDL and non-HDL cholesterol, and triglycerides [SMD -0.87 mmol/L (95\% CI -0.99, -0.76); -0.56 mmol/L (95\% CI -0.67, -0.45); -0.88 mmol/L (95\% CI -0.99, -0.76); and -0.56 mmol/L (95\% CI -0.75, -0.36), respectively], but HDL cholesterol did not differ [-0.16 mmol/L (95\% CI -0.49, 0.16)]. In the atazanavir/ritonavir versus atazanavir comparison (two RCTs), total [SMD 0.44 mmol/L (95\% CI 0.23, 0.65)] and non-HDL cholesterol [SMD 0.44 mmol/L (95\% CI 0.23, 0.65)] were higher, but HDL cholesterol, LDL cholesterol and triglycerides were not different. CONCLUSIONS: At 48 weeks, plasma lipid concentrations were lower with atazanavir/ritonavir than with other ritonavir-boosted protease inhibitor regimens. Total and non-HDL cholesterol were higher with atazanavir/ritonavir than atazanavir alone. This article was published in J Antimicrob Chemother and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version